Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. retained Axinn, Veltrop & Harkrider LLP to defend them in a recently-filed litigation in the U.S. District Court for the District of Delaware, Millennium Pharm., Inc. v. Zydus Pharm. (USA) Inc., 17-cv-423.
In this Hatch-Waxman case, Millennium asserts that Zydus and Cadila infringe U.S. Patent Nos. 6,713,446 and 6,958,319, which have been listed in FDA’s Orange Book for the brand product Velcade®. Velcade® for Injection (bortezomib) is a proteasome inhibitor for intravenous or subcutaneous administration used to treat patients with multiple myeloma or mantle cell lymphoma. Estimated U.S. sales of Velcade® are over $1 billion annually.
The Axinn team representing Zydus and Cadila includes Chad Landmon, Thomas Hedemann, Dan-Feng Mei and Rebecca Clegg.